Austin Hospital Launches World-First Lymphoma Trial

A hospital in Austin just made medical history by giving hope to people fighting an aggressive form of blood cancer.

St. David's South Austin Medical Center became the first site worldwide to enroll a patient in a phase 3 clinical trial for rondecabtagene autoleucel, a next-generation therapy for large B-cell lymphoma. The treatment builds on existing CAR T-cell therapy but packs a more powerful punch against cancer cells that learn to hide from traditional approaches.

Here's what makes this different. Current CAR T-cell therapy uses a patient's own immune cells, genetically modified to hunt down cancer by targeting a specific marker called CD19. But some lymphomas are clever. They turn off their CD19 markers and essentially become invisible to the treatment.

The new ronde-cel therapy targets both CD19 and CD20 markers, giving cancer nowhere to hide. The modified T-cells also stick around longer in the body, creating a more sustained attack.

"This is a way to really have a robust attack and to not give the lymphoma any chances to come back," said Dr. Uttam Rao, the principal investigator for the study at St. David's South Austin.

The trial is enrolling 400 patients internationally and comparing ronde-cel with traditional CAR T-cell therapy. Researchers will track patients for 18 months to see if the lymphoma returns and whether the new treatment causes fewer life-threatening side effects than current options.

What's especially promising is that patients can now skip straight to ronde-cel after chemotherapy fails, rather than waiting through multiple treatment rounds. That means faster access to potentially life-saving care.

The Ripple Effect

The benefits extend beyond the trial itself. St. David's South Austin just partnered with Texas Oncology to bring advanced blood cancer care closer to patients' homes. Doctors from St. David's now see patients at Texas Oncology's Round Rock clinic, reducing travel time for specialized care.

Before this partnership, Round Rock patients needed to drive to Austin repeatedly for treatments and follow-up appointments. Now they can receive most of their care locally, with only the most specialized procedures requiring a trip to St. David's South Austin.

Dr. Debra Patt of Texas Oncology said the collaboration means "patients have access to the most advanced treatments close to home." The organizations are already exploring similar partnerships at other Central Texas locations.

For people battling blood cancers, this combination of cutting-edge treatment and convenient care represents real progress in a fight where every advantage matters.